My skepticism on Lilly (LLY)
hasn't paid off so well of late, with the stock up about 12% over the
last quarter and nearly 7% for the year to date. That said, I still
think this company has a lot left to prove in terms of its pipeline
quality and future expense structure. The stock is on a solid run, but
this still wouldn't be among my choices for new money in Big Pharma.
Please read more here:
The Next 12-18 Months Will Shape Lilly's Future
No comments:
Post a Comment